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Abstract: Cerebral near-infrared spectroscopy (NIRS) oximetry may help clinicians to improve
patient treatment. However, the application of NIRS oximeters is increasingly causing confusion
to the users due to the inconsistency of tissue oxygen haemoglobin saturation (StO2) readings
provided by different oximeters. To establish a comparability of oximeters, in our study we
performed simultaneous measurements on the liquid phantom mimicking properties of neonatal
heads and compared the tested device to a reference NIRS oximeter (OxiplexTS). We evaluated
the NIRS oximeters FORE-SIGHT, NIRO and SenSmart, and reproduced previous results with
the INVOS and OxyPrem v1.3 oximeters. In general, linear relationships of the StO2 values with
respect to the reference were obtained. Device specific hypoxic and hyperoxic thresholds (as used
in the SafeBoosC study, www.safeboosc.eu) and a table allowing for conversion of StO2
values are provided.
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1. Introduction
Near-infrared spectroscopy (NIRS) is a technique for measuring oxygenation of tissue non-
invasively and continuously. One important application may be to prevent cerebral haemorrhagic
and ischaemic insults in preterm infants. A randomized controlled trial safeguarding the
brains of our smallest children (SafeBoosC) showed that it is possible to reduce the cerebral
hypoxic/hyperoxic burden in extremely preterm infants, when combining NIRS monitoring with a
treatment guideline [1]. This also led to a substantially reduced mortality and incidence of severe
brain lesions in the treatment group. However, this reduction was not statistically significant and
therefore a large study is planned to confirm the clinical benefits. One major issue here is that
different brands of NIRS oximeters provide systematically different oxygenation values, as shown
by numerous studies [2–8]. Currently, tissue oxygen haemoglobin saturation (StO2) values cannot
be compared between different oximeters and sensors [9, 10]. This constitutes a problem when
setting alarm limits in the mentioned new trial or when interpreting the literature [11].
Why do different NIRS oximeters provide different values? NIRS oximeters measure absolute
values of the StO2, which represents the proportion of oxygenated haemoglobin of all haemoglobin
present in arterial, capillary and venous compartments of the tissue interrogated by the sensor.
The reason for the different values between different brands is that it is difficult to validate. One
StO2 in vivo approach is to take arterial and venous (jugular vein for cerebral measurements)
blood samples and to determine their oxygen haemoglobin saturation (SO2) by co-oximetry, a
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trusted method.
An ethical problem here is that venous blood samples from the jugular bulb cannot be collected
without risk to the patient [12]. In particular in preterm infants, sampling the jugular bulb is
clinically not feasible. For ethical reasons, these studies are therefore typically either performed
in healthy young adults or patients requiring a jugular bulb catheter for clinical reasons. For
the latter an influence of their pathology is likely. Both scenarios may not be considered fully
representative of the wide range of patients in hospitals.
A methodological problem is that the venous jugular bulb blood represents an average of
the whole brain hemisphere, which is much larger than the volume of the NIRS measurement
it is being compared to [13]. In addition, there may be extra-cerebral contamination [14]. To
determine the StO2 the arterial-to-venous volume ratio (AVR) has to be assumed (typically
25:75 % or 30:70 %). Although a positron emission tomography (PET) study estimated AVR
to be 30:70 [15], this is a source of errors, because the AVR was shown to vary considerably
between individuals [16–18]. Furthermore, the AVR depends on the specific location measured
and it changes over time [19], in particular during desaturation experiments [2]. The AVR is
further influenced by e.g. the end tidal CO2, which must be kept constant [20] and the subject’s
positioning [2] which may cause systematic differences between studies. A change in the group
AVR assumption by 10 % (i.e. 20:80 % or 40:60 %) causes a change in bias of already ±3% [20].
But a recent meta-analysis on published cerebral StO2 acquired with the INVOS oximeter reported
that even higher AVR of up to 75:25 % fit their data best [21]. These examples show that already
the in vivo reference StO2 is associated with a number of assumptions and uncertainties on
group and patient levels, is subject to considerable random and systematic errors, and does not
constitute a ’gold standard’.
Apart from problems with the reference StO2, there are further problems encountered during in
vivo validation by desaturation studies: Although short episodes of hypoxia with arterial oxygen
haemoglobin saturation (SaO2) as low as 50-70% are tolerated well by healthy adults [22], the
very low range of StO2 cannot be validated safely with this method, leaving questions on the
validity of extreme (high and low) readings which may occur in clinical situations.
Another issue is that changes in StO2 originate from the brain and partly from extra-cerebral
layers. In adults a significant influence of scalp and skin on the cerebral StO2 values was
found [23,24] even though the effect of the skull layer, which is likely substantial [25, 26], was
neglected. However, StO2 is changed everywhere and not only in the brain in desaturation studies.
Thus, the ability of a NIRS oximeter to measure brain StO2 independently of the more superficial
tissues is not assessed by current methods.
A desaturation study comparing several cerebral oximeters found ’significantly more positive
bias at lower SaO2’ in some oximeters [2], which corresponds to lower sensitivity to oxygenation
changes. The difference between oximeters is striking, because most oximeters in that study were
calibrated by this method of arterial and venous blood sampling. Hence, this approach results in
inconsistent StO2 values between different instruments, and therefore seems inappropriate for
validation of cerebral StO2.
A further option for in vivo validation is the vascular occlusion test on extremities. The
ischaemia induced by the occlusion allows a wide range of StO2, but otherwise the same
mentioned issues as for the brain remain unresolved.
Phantoms, on the other hand, have the advantage of controllable optical properties and can
be adjusted for specific research questions and may include sophisticated geometries. In 1993,
Firbank et. al. recommended a solid phantom made of optically clear polyester resin. Dyes and
titanium dioxide were added to adjust its optical properties [27]. 3D printers allow producing
anatomically accurate, tissue-equivalent phantoms of infant heads [28] and mice [29]. However,
since oximeters include a different set of wavelengths each, it is more appropriate to include real
hemoglobin to obtain an accurate absorption spectrum. In addition, StO2 and total haemoglobin
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concentration (ctHb) can be changed over the entire relevant range [30–33]. One example is
the "dynamic phantom brain model" [34]. This model consisted of (1) a resin with a vascular
network (500 µm diameter) which represents brain and is perfused by human blood, (2) a bubble
oxygenator to change the oxygenation of the blood and (3) a roller pump [34]. Another method
is to fabricate microtubes for the vascular network [35]. The diameter of these microtubes,
however, was still larger (300 µm inner diameter) than the one of human capillaries (9 µm (inner
diameter)) [36] which is a relevant difference for NIRS oximetry [37].
The most promising method to compare NIRS devices in our opinion is a dynamic 2-layer
phantom with adjustable optical properties mimicking the neonatal head as described in detail
in [38]. This phantom contains Intralipid to adjust scattering and real human haemoglobin. The
aim was to apply this phantom to quantitatively compare different NIRS devices for SafeBoosC
to establish comparable intervention thresholds between devices. We provided mathematical
equations to convert StO2 between devices. We demonstrated that the systematic differences in
the StO2 values between NIRS oximeters also depend on the ctHb of the phantom, which may be
due to different assumptions regarding background absorbers [39].
In our previous comparison studies in phantoms [38,40–42] we observed substantial systematic
differences between in vivo calibrated NIRS oximeters. Such differences were also shown in
vivo [2–8] and are probably due to the error prone in vivo calibration rather than the simple
nature of the phantom [20]. The oximeters included in [38] and here can be assumed to apply the
multi-distance approach for calculation of StO2, since they provide more than one source-detector
separation. Such oximeters are minimally influenced by a superficial layer of 2.5 mm [26,42]
independent of epidermal pigmentation which leads to a lower intensity of detected light, thus
lowering the SNR. Therefore, our phantom model with a static superficial layer is an appropriate
model for neonates. We included adult sensors in our experiments since adult sensors have been
used off-label in neonates. In adults the skull/scalp/skin region is > 1 cm thick and extra-cerebral
signals contribute substantially to the StO2. Therefore, the results are not to be translated to adults.
Although it is currently unclear how a good model of the adult head can be achieved best, we have
shown that phantoms like ours have the capability to assess sensitivity of instruments to deeper
layers [42]. Phantoms provide for simultaneous measurements by different NIRS oximeters on
truly the same sample and over a wide StO2 range. Even though not yet fully completed, it
is possible to include a precise and accurate StO2 reference for validation of accuracy. Thus,
phantoms are a versatile tool to validate NIRS oximeters reproducibly.
In this paper, the aim was to extend our previous work [38] with a new set of devices and
sensors to provide clinical researchers and clinicians a means to translate neonatal cerebral
StO2 acquired by their oximeter to the results reported by others, using other oximeters. The
three additional oximeters NIRO-200NX (Hamamatsu), FORE-SIGHT Elite (Casmed) and
SenSmart-X100 (Nonin) were compared with OxiplexTS (ISS) as a reference. Measurements
for the INVOS 5100C (Medtronic) and OxyPrem v1.3 (in-house developed, University Hospital
Zurich) oximeters were repeated with the aim to test reproducibility of the liquid phantom
method.
2. Material and methods
2.1. NIRS oximeters
Some of the instruments used in [38] and this experiment were calibrated in vivo, which only
probes a limited range of StO2 safely [20,43–47]. In neonates, however, StO2 often lies and is
considered outside this calibrated range. We thus report data from the whole range recorded. We
solely describe oximeters and sensors tested for the first time with this method. For a description
of previously tested devices please refer to [38].
The NIRO-200NX (Hamamatsu Photonics K.K., Hamamatsu, Japan) applies an LED source
with three wavelengths (735 nm, 810 nm, 850 nm) in disposable adhesive (NIRO small/ NIRO
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large) and re-usable (NIRO small RU/NIRO large RU) sensors with source-detector separation
(SDS) of 3 cm (small) and 4 cm (large). Detectors of the disposable sensors and the re-usable
probes have different shapes. The device combines modified Beer-Lambert law and spatially
resolved spectroscopy for trend and absolute measurements. It is approved for clinical use.
The FORE-SIGHT Elite (CAS Medical Systems, Inc., Branford, CT, USA) applies five
wavelenghts (690, 730, 770, 810, and 870 nm) to measure absolute StO2. The large sensor
(FORE-SIGHT adult) comprises SDS of 1.5 and 5 cm while the medium sensor (FORE-SIGHT
medium) has SDS of 1.3 and 4 cm. Small sensors for neonates use SDS of 1 and 2.5 cm and
are available as adhesive (FORE-SIGHT small) and non-adhesive version (FORE-SIGHT small
band). The device is approved for clinical use.
The SenSmart-X100 (Nonin Medical, Inc., Plymouth, MN, USA) applies four wavelengths
(730, 760, 810 and 870 nm). The sensors have two light sources and two detectors giving four
light paths with SDS of 2 and 4 cm in case of the adult sensor EQUANOX Advance 8004CA
(SenSmart adult). The device is approved for clinical use.
The device we used as reference here, OxiplexTS (ISS, Champaign, Illinois, USA), employs
two modulated light sources (692 nm and 834 nm) measuring absolute tissue absorption and
reduced scattering coefficients. A rigid sensor with four SDS (2.5 cm, 3.0 cm, 3.5 cm and 4.0
cm) was applied. In contrast to other tissue oximeters, this device is not approved for clinical
use, but has a CE mark for research. As we solely intended to compare instruments and not
to assess accuracy, our reference does not have to measure the true StO2, but only needs to
measure reproducibly and independent of ctHb and reduced scattering coefficient (µ′s). OxiplexTS
measures both absorption coefficient (µ′a) and µ′s and was validated in several publications such
as [26,39,48] and in vivo a precision of 2.0 % was demonstrated in term-born newborns [49],
thus fulfilling our needs.
2.2. Phantom setup
As in the previous systematic in vitro comparison of NIRS oximeters [38], the setup consisted of
a container offering four windows for simultaneous recording with NIRS sensors. Each window
was made of a layer of silicone with tailored optical properties and thickness (2.5 mm) to resemble
the scalp and skull of a typical neonate. The container was filled with a liquid containing human
haemoglobin (Hb) and Intralipid (IL) which was added to obtain the wanted µ′s of ≈ 5.5 cm−1.
Each phantom preparation covered typical ctHb in neonates (see Table 1). OxiplexTS (ISS, Inc.,
Champaign, IL, USA) was applied as a reference oximeter. The investigation was performed in
three phantoms on three different days.
2.2.1. Phantom no. 1
The FORE-SIGHT Elite with FORE-SIGHT small and FORE-SIGHT small band as well as
NIRO small were investigated with one deoxygenation per liquid mixture. Then FORE-SIGHT
small, FORE-SIGHT small band and NIRO small were removed, remounted and another three
deoxygenations were performed. FORE-SIGHT small reported an ’out of range’ error in this
period and did not provide data.
2.2.2. Phantom no. 2
Two groups of oximeters were investigated: Group 1 with SenSmart adult, FORE-SIGHT adult
and NIRO large; Group 2 with FORE-SIGHT medium, NIRO small RU and NIRO large RU.
Groups 1 and 2 were intermittently placed on the phantom. Two deoxygenations at a ctHb = 30µM
were performed with group 1 before switching to group 2 and performing another one. Then ctHb
was increased to 47.5 µM and one deoxygenation was first measured with group 2 followed by
group 1. After increasing ctHb to 75 µM, there were first two deoxygenations recorded with group
1 and then one with group 2.
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2.2.3. Phantom no. 3
Here, the INVOS 5100C with adult SomaSensor SAFB-SM (INVOS adult), OxyPrem v1.3
and SenSmart adult were employed. For ctHb = 30 µM and 75 µM one deoxygenation each was
performed. At ctHb = 47.5 µM we performed several deoxygenations and removed and mounted
the sensors in-between them to test robustness to repositioning. During the second ctHb = 47.5µM
deoxygenation new sensors for INVOS adult and SenSmart adult were used and afterwards the
original ones were reapplied.
2.3. Liquid mixture
Table 1. Amount of blood added and resulting ctHb and htc of the liquid phantoms for each
of the three mixtures.
Phantom no.1 Phantom no.2 Phantom no.3
Mixture ctHb Blood ctHb htc Blood ctHb htc Blood ctHb htc
no. ( µM) (ml) ( µM) (%) (ml) ( µM) (%) (ml) ( µM) (%)
1 ≈ 30 24 30.67 0.60 22 28.20 0.55 22 28.20 0.55
2 ≈ 47.5 39 49.56 0.97 37 47.16 0.92 37 47.16 0.92
3 ≈ 75 61 76.86 1.51 59 74.57 1.46 62 78.28 1.53
The phantom consisted of the same ingredients as in [38], obtained from the same suppliers.
Main ingredient was phosphate buffered saline (PBS) (Kreis, pH = 7.4) with a volume of 2.5 l to
which 74 ml IL (20 %) and defined amounts of blood were added. We added sodium bicarbonate
buffer (SBB) (8.4% ≡ 1 mmol/ml) initially (15 ml) and each time when adding blood to the
phantom (10ml). We added 3 g of yeast solved in a small amount of SBB and 3ml glucose (50%)
solution to the phantom to trigger deoxygenation. Each time blood was added, another 3 ml of
glucose were added. The phantom was re-oxygenated by adding pure oxygen (O2) by bubbling.
In [38], we covered the typical range of ctHb in neonates with ctHb = 25 µM, 45 µM and 70 µM.
Here we adhered to these values. Table 1 shows the amounts of blood added and the effective
ctHb of each phantom. Two erythrocyte concentrates with the same measured ctHb ≡ 215 g/l and
htc ≡ 65.5 % were employed, one for phantom 1 and one for phantoms 2 and 3.
2.4. Data extraction and analysis
To ensure consistency, data processing methods were the same as in [38]. We applied the same
StO2 limits for fitting to both axes, i.e. to OxiplexTS and the oximeter to be investigated. However,
here we set the upper limit to StO2 = 85 % (instead of 94 %) because StO2 of FORE-SIGHT
Elite was non-linear above this value for all sensors. The lower limit was kept at StO2 = 16 %.
3. Results
Figures 1(a)-1(d) and 2(a)-2(d) show StO2 of the oximeters investigated for the first time, whereas
Fig. 3(a) and 3(b) show the results of two oximeters already included in [38]. We added the
data from [38] to the same plots for comparison. Table 2 shows the coefficients for linear fits
in the range 16 ≤ StO2 ≤ 85 % and their generally high correlation coefficients (R2) except for
SenSmart adult showing a remarkable curvature. We do not report results of FORE-SIGHT
medium due to inconsistency with data obtained in another experiment (not published).
Table 3 shows the hypoxic (StO2 = 55 %) and hyperoxic thresholds (StO2 = 85 %) defined
by the SafeBoosC study based on the INVOS adult sensor. To generate table 3, we took the
corresponding StO2 thresholds of the OxiplexTS of (StO2 = 47.0 % and StO2 = 77.2 %)
as determined in [38] for data at ctHb = 47.5 µM. We then applied linear functions with the
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coefficients listed in table 2 for x = 47 %, 77.2 %. Table 3 also lists the uncertainty of StO2
readings determined by subtracting the threshold at ctHb = 75 µM from the one at ctHb = 30 µM.
In [38], we provided a table for converting StO2 from one oximeter to another for typical
neonates for mixture 2 (ctHb = 45 µM in [38], ctHb = 47.5 µM in present study). In tables 4-6 new
data are complemented with reprinted results of [38] in italic.
We recorded pH and temperature (T) by repeated measurements in all three phantoms. Overall,
pH was in the range 7.13 ≤ pH ≤ 7.64 with a general decrease over time and an increase during
bubbling of O2. Values of temperature were in the range 35.1 ◦C ≤ T ≤ 36.4 ◦C with a variation
of ≈ 0.5 ◦C within each single phantom. µ′s as measured by OxiplexTS decreased by 11 % from
baseline the end of phantom 1 (after 210 minutes), by 16 % at the end of phantom 2 (after 275
minutes) and by 9 % at the end of phantom 3 (after 160 minutes).
Table 2. Coefficients for linear transformation StO2, Devicex = a ∗ StO2, OxiplexTS + b.
ctHb = 30 µM ctHb = 47.5 µM ctHb = 75 µM
b a R2 b a R2 b a R2
FORE-SIGHT small 51.0 0.35 0.998 43.5 0.47 0.997 35.6 0.57 0.994
FORE-SIGHT small band 52.0 0.37 0.998 44.1 0.48 0.997 37.3 0.57 0.994
NIRO small 41.6 0.45 1.000 32.9 0.60 0.999 28.1 0.66 0.999
NIRO small RU 41.9 0.49 0.999 36.1 0.57 0.999 28.1 0.68 0.999
INVOS adult 18.8 0.83 0.999 5.0 1.04 0.998 -11.3 1.28 0.999
OxyPrem V1.3 24.0 0.69 1.000 19.5 0.74 0.998 13.6 0.83 0.998
SenSmart adult 2.7 0.56 0.983 -12.8 0.85 0.992 -34.1 1.21 0.991
FORE-SIGHT adult 39.8 0.48 0.995 40.1 0.52 0.994 29.6 0.66 0.995
NIRO large 36.4 0.65 1.000 26.7 0.75 1.000 15.2 0.92 0.998
NIRO large RU 36.6 0.61 1.000 29.6 0.69 1.000 21.7 0.81 0.999
Table 3. SafeBoosC intervention thresholds for ctHb = 47.5 µM and range of uncertainty due
to variation of ctHb in the range of 30 µM to 75 µM (threshold at ctHb = 75 µM - threshold at
ctHb = 30 µM). All values are given as StO2 [%].
hypoxic uncertainty hyperoxic uncertainty
threshold range threshold range
due to ctHb due to ctHb
Oxiplex TS 47.0 77.2
FORE-SIGHT small 65.5 4.9 79.6 -1.8
FORE-SIGHT small band 66.7 5.3 81.2 -0.8
NIRO small 61.0 3.5 79.1 -3.0
NIRO small RU 62.8 4.8 80.0 -1.0
INVOS adult 53.7 9.1 84.9 -4.3
OxyPrem V1.3 54.3 3.6 76.7 -0.7
SenSmart adult 27.3 6.1 53.0 -13.7
FORE-SIGHT adult 64.7 2.0 80.5 -3.4
NIRO large 61.9 8.4 84.6 0.1
NIRO large RU 62.2 5.7 83.2 -0.3
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Fig. 1. (a) FORE-SIGHT small with fixation band vs. OxiplexTS for three different ctHb. Data
was obtained in phantom 1. The sensor was repositioned after the 1st of 4 deoxygenations
at ctHb = 75 µM. (b) FORE-SIGHT small adhesive vs. OxiplexTS measured in phantom
1. (c) FORE-SIGHT adult vs. OxiplexTS in phantom 2. The sensor was repositioned after
ctHb = 30 µM. There were two consecutive deoxygenations at ctHb = 30 µM and 75 µM.
(d) SenSmart adult vs. OxiplexTSmeasured in phantom 2 and 3. In phantom 2, the sensor was
repositioned after ctHb = 30µM. There were two consecutive deoxygenations at ctHb = 30µM
and 75 µM. In phantom 3, there were 3 deoxygenations with sensor repositioning in between
at ctHb = 47.5 µM with the second one being performed with a new sensor.
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Fig. 2. (a) NIRO-200NX small reusable vs. OxiplexTS three different ctHb measured in
phantom 2. The sensor was repositioned after ctHb = 47.5 µM. (b) NIRO-200NX small
single-use vs. OxiplexTS in phantom 1. The sensor was repositioned after the 1st of 4
deoxygenations at ctHb = 75 µM. (c) NIRO-200NX large reusable vs. OxiplexTS in phantom
2. The sensor was repositioned after ctHb = 47.5 µM. (d) NIRO-200NX large single-use vs.
OxiplexTS in phantom 2. The sensor was repositioned after ctHb = 30 µM. There were two
consecutive deoxygenations at ctHb = 30 µM and 75 µM.
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Fig. 3. (a) INVOS adult vs. OxiplexTS for three different ctHb measured in phantom 3.
There were 3 deoxygenations with sensor repositioning in between at ctHb = 47.5 µM
with the second one being performed with a new sensor. Data from [38] is marked with
(old). (b) Oxyprem v1.3 vs. OxiplexTS in phantom 3. There were 2 deoxygenations at
ctHb = 47.5 µM with sensor repositioning in between. Data from [38] is marked with (old).
Table 4. Coefficients for linear transformation of StO2 [%] from any oximeter to the scale of
oximeters investigated in [38]: StO2,to = a ∗ StO2,from + b. Coefficients were determined at
ctHb = 47.5 µM. Data at ctHb = 45 µM reprinted from [38] are printed italic. Part 1.
OxiplexTS OxyPrem INVOS INVOS SenSmart
to→ v1.3 adult neonatal neonatal
from ↓ b a b a b a b a b a
Oxiplex TS 0.0 1.00 21.3 0.71 8.1 1.00 11.8 1.09 47.1 0.41
OxyPrem v1.3 -30.0 1.41 0.0 1.00 -21.9 1.41 -21.0 1.54 34.8 0.58
INVOS adult -8.1 1.00 15.6 0.71 0.0 1.00 3.0 1.10 43.8 0.41
INVOS neonatal -10.8 0.91 13.6 0.65 -2.7 0.91 0.0 1.00 42.7 0.38
SenSmart neonatal -114.9 2.44 -60.1 1.73 -106.4 2.43 -113.8 2.67 0.0 1.00
FORE-SIGHT small -93.1 2.14 -44.7 1.52 -84.7 2.13 -90.0 2.34 8.9 0.88
FORE-SIGHT small band -91.9 2.08 -43.9 1.48 -83.5 2.08 -88.7 2.28 9.4 0.85
NIRO small -54.9 1.67 -17.7 1.18 -46.7 1.67 -48.3 1.83 24.6 0.69
NIRO small RU -63.5 1.76 -23.7 1.25 -55.2 1.75 -57.6 1.92 21.1 0.72
INVOS adult -4.8 0.97 17.9 0.68 3.2 0.96 6.5 1.06 45.1 0.40
OxyPrem V1.3 -26.4 1.35 2.6 0.96 -18.2 1.35 -17.0 1.48 36.3 0.55
SenSmart adult 15.0 1.17 31.9 0.83 23.0 1.17 28.2 1.28 53.3 0.48
FORE-SIGHT adult -76.5 1.91 -33.0 1.35 -68.2 1.90 -71.9 2.09 15.7 0.78
NIRO large -35.6 1.33 -4.0 0.95 -27.4 1.33 -27.1 1.46 32.5 0.55
NIRO large RU -42.7 1.44 -9.0 1.02 -34.5 1.44 -34.9 1.58 29.6 0.59
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Table 5. Coefficients for linear transformation of StO2 [%] from any oximeter to the
scale of any other oximeter: StO2,to = a ∗ StO2,from + b. Coefficients were determined at
ctHb = 47.5 µM. Names of oximeters investigated in [38] at ctHb = 45 µM are printed italic.
Part 2.
FORE-SIGHT FORE-SIGHT NIRO NIRO INVOS
to→ small small band small small RU adult
from ↓ b a b a b a b a b a
OxiplexTS 43.5 0.47 44.1 0.48 32.9 0.60 36.1 0.57 5.0 1.04
OxyPrem v1.3 29.5 0.66 29.7 0.68 14.9 0.84 19.0 0.80 -26.1 1.46
INVOS adult 39.7 0.47 40.2 0.48 28.0 0.60 31.5 0.57 -3.4 1.04
INVOS neonatal 38.5 0.43 38.9 0.44 26.4 0.55 30.0 0.52 -6.2 0.95
SenSmart neonatal -10.2 1.14 -11.0 1.17 -35.9 1.46 -29.2 1.39 -113.9 2.52
FORE-SIGHT small 0.0 1.00 -0.6 1.03 -22.8 1.28 -16.8 1.22 -91.3 2.21
FORE-SIGHT small band 0.5 0.97 0.0 1.00 -22.1 1.25 -16.2 1.19 -90.2 2.16
NIRO small 17.8 0.78 17.7 0.80 0.0 1.00 4.9 0.95 -51.9 1.73
NIRO small RU 13.8 0.82 13.7 0.84 -5.1 1.05 0.0 1.00 -60.7 1.82
INVOS adult 41.3 0.45 41.8 0.46 30.0 0.58 33.4 0.55 0.0 1.00
OxyPrem V1.3 31.2 0.63 31.5 0.65 17.1 0.81 21.1 0.77 -22.3 1.40
SenSmart adult 50.5 0.55 51.3 0.56 41.9 0.70 44.7 0.67 20.6 1.21
FORE-SIGHT adult 7.7 0.89 7.4 0.92 -12.9 1.14 -7.4 1.09 -74.2 1.98
NIRO large 26.9 0.62 27.0 0.64 11.6 0.80 15.8 0.76 -31.9 1.38
NIRO large RU 23.6 0.67 23.6 0.69 7.3 0.86 11.8 0.82 -39.2 1.49
Table 6. Coefficients for linear transformation of StO2 [%] from any oximeter to the
scale of any other oximeter: StO2,to = a ∗ StO2,from + b. Coefficients were determined at
ctHb = 47.5 µM. Names of oximeters investigated in [38] at ctHb = 45 µM are printed italic.
Part 3.
OxyPrem SenSmart FORE-SIGHT NIRO NIRO
to→ v1.3 adult adult large large RU
from ↓ b a b a b a b a b a
OxiplexTS 19.5 0.74 -12.8 0.85 40.1 0.52 26.7 0.75 29.6 0.69
OxyPrem v1.3 -2.7 1.04 -38.4 1.20 24.4 0.74 4.2 1.06 8.8 0.98
INVOS adult 13.5 0.74 -19.7 0.86 35.9 0.53 20.6 0.75 24.0 0.70
INVOS neonatal 11.5 0.68 -22.0 0.78 34.4 0.48 18.6 0.69 22.1 0.63
SenSmart neonatal -65.5 1.81 -110.8 2.08 -20.1 1.28 -59.4 1.83 -50.1 1.69
FORE-SIGHT small -49.4 1.58 -92.2 1.82 -8.7 1.12 -43.1 1.60 -34.9 1.48
FORE-SIGHT small band -48.5 1.54 -91.2 1.78 -8.1 1.09 -42.2 1.56 -34.1 1.45
NIRO small -21.2 1.24 -59.7 1.43 11.3 0.88 -14.5 1.25 -8.5 1.16
NIRO small RU -27.5 1.30 -67.0 1.50 6.8 0.92 -20.9 1.32 -14.4 1.22
INVOS adult 16.0 0.72 -16.9 0.82 37.6 0.51 23.1 0.72 26.3 0.67
OxyPrem V1.3 0.0 1.00 -35.3 1.15 26.3 0.71 6.9 1.01 11.3 0.94
SenSmart adult 30.7 0.87 0.0 1.00 48.0 0.61 38.0 0.88 40.0 0.81
FORE-SIGHT adult -37.1 1.41 -78.1 1.63 0.0 1.00 -30.7 1.43 -23.5 1.32
NIRO large -6.8 0.99 -43.2 1.14 21.4 0.70 0.0 1.00 4.9 0.93
NIRO large RU -12.1 1.07 -49.2 1.23 17.7 0.76 -5.3 1.08 0.0 1.00
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4. Discussion
This study is an extension to the study in [38] with the aim to provide clinical researchers and
clinicians a means to translate neonatal cerebral StO2 acquired by their oximeter to the results
reported by others, using other oximeters. As we used the same methods, we do not repeat the
general discussion about aspects of the phantom but focus on new findings.
4.1. Observations
Relations between all oximeters investigated and OxiplexTS were linear except for these
exceptions: (1) Fig. 1(a), 1(b) and 1(c) reveal that the FORE-SIGHT Elite oximeter is less
sensitive to oxygenation changes for StO2 > 85 %. Here the relation is non-linear. This does
not affect the coefficients because we set the fitting range 16 ≤ StO2 ≤ 85 % to circumvent this
problem. The slightly smaller fitting range compared to [38] does not affect the results because
there was little noise and all relations were linear with high R2 (Table 2) except for SenSmart adult
(see (3) below). (2) In Fig. 2(b) the ctHb = 30 µM curve of NIRO small is bent at StO2 > 85 %,
which has no influence on the results. This coincides with a manual pH measurement. It is
probable that the hand-held pH-probe accidentally partially obstructed the light path of the
sensor. (3) SenSmart adult to OxiplexTS relation is non-linear (Fig. 1(d)). We have observed
this already in a previous study [42]. Although the linear fits (Table 2) here depend on the StO2
range of fitting, we consider the deviation from the fit lines acceptable within the fit range, but
extrapolation to higher or lower StO2 is inaccurate.
Not all manufacturers published their algorithms and therefore it is unknown why instruments
over-/underestimate StO2. One reason may be unaccounted absorbers such as water (H2O) present
in the phantom, particularly during low ctHb [39]. The phantom contains v 98 % H2O and is
similar to brain tissue of neonates with up to 95 % H2O [50]. This is discussed in detail in [38].
We observed a decrease in phantom µ′s over time. The µ′s depends on the number and size of
sub-micrometer lipid droplets of the IL emulsion and their relative refractive index. We assume
the decrease in µ′s to be caused by confluence of these droplets into larger droplets. The StO2
errors due to the variation in µ′s were small. In repeated deoxygenations, there is no relevant
deviation visible (Fig. 1(a), 1(c), 1(d), 2(b), 2(d), 3(a), and 3(b)) except for the small one due to
sensor repositioning (< 2 %, see Sec. 4.3). We therefore conclude that the phantom experiments
may last up to 4.5 hours, as long as the decrease in µ′s is in the range of this experiment (≤ 16 %).
We cannot tell why an error was reported after removal and reattachment of the adhesive
sensor (FORE-SIGHT small). The values of this sensor agreed well to FORE-SIGHT small band
beforehand (see Table 2), as expected since both sensors apparently are similar.
We do not report results for FORE-SIGHT medium, because its response at ctHb = 75 µM
compared to the response at the lower ctHb was too different from the patterns observed with the
large and both small sensors of the same oximeter. FORE-SIGHT medium data from another,
unpublished experiment also showed different patterns for all three ctHb. Simultaneous StO2
readings of NIRO small RU agreed well with another unpublished experiment. Thus, we exclude
phantom 2 as reason for this deviation. We also exclude inadequate sensor placement because the
sensor was repositioned several times. Probably the specific sensor used was simply defective
and consequently we do not report results for FORE-SIGHT medium.
The non-linear behavior for the SenSmart adult was also observed in a previous phantom
study [42], but with remarkably stronger curvature in the present study (Fig. 1(d)). In phantom
3 at ctHb = 47.5 µM, one measurement with a brand new SenSmart adult sensor agrees well
with the other measurements (Fig. 1(d)). We therefore exclude a sensor defect. SenSmart adult
was used in two different phantoms and the sensor was repositioned several times, hence we
exclude inadequate sensor placement. Simultaneous readings of other oximeters in both phantoms
were inconspicuous. We consequently exclude the phantoms 2 and 3 as reasons causing this
observation. One difference between the present study and [42] are the different optical properties
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for the windows. Both sets of windows were made from the same ingredients, but different
quantities. At 692 and 834 nm, respectively, the windows of current study and [38] had µ′a of
0.059 and 0.057 [1/cm], and µ′s of 5.0 and 4.4 [1/cm], while the windows of [42] had µ′a of 0.10
and 0.11 [1/cm], and µ′s of 9.6 and 8.3 [1/cm]. Accordingly, we speculate that in contrast to other
oximeters, SenSmart adult may be sensitive to optical properties of the superficial layer, although
it is only 2.5 mm thick. We decided to report results of SenSmart adult for comparison to [42],
but this issue needs to be further investigated.
4.2. Comparison to in vivo findings
Hessel et al. compared INVOS neonatal and an older version of FORE-SIGHT small in neonates
directly after birth [4]. They simultaneously recorded with sensors placed on separate hemispheres
of the head. Their StO2 data is plotted in Fig. 4 with the fit line we obtained in vitro ctHb = 47.5µM
(table 4). The line lies within the point clouds, demonstrating that our in vitro agree reasonably
well with in vivo data [4]. Please note that the old FORE-SIGHT instrument had 4 wavelengths
generated by laser diodes, while the new FORE-SIGHT Elite used here employed 5 wavelengths
generated by LEDs. Thus the instruments are quite different. We did not find any literature
comparing the two versions of the instrument with neonatal sensors. Assuming that the older
and the new version of the instrument provide similar StO2 values, Figure 4 would indicate
reasonable agreement between in vivo and in vitro measurements which adds plausibility to our
in vitro evaluation.
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Fig. 4. In vivo comparison [4] of simultaneous StO2 recordings in neonates with the old
FORE-SIGHT instrument (FS1) with small sensor and INVOS neonatal as scatter density
plot (gray dots, darker means higher occurrence). The red line corresponds to the deming
regression [51] of this data (y = 1.98x − 73.7). This agrees reasonably with the relation
(dashed green line) we obtained in this in vitro phantom study with the new FORE-SIGHT
Elite instrument (FS Elite) at ctHb = 47.5 µM (y = 2.34x − 90, see Table 4).
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4.3. Reproducibility of the method
In our study, sensors were un-mounted and re-mounted between repeated measurements at the
same ctHb (Fig. 1(a), 2(b), 1(d), 3(a), and 3(b)). The sensor repositioning causes slight variation
in sensor location and pressure applied to the window. Repositioning errors were < 2 % StO2,
which we consider acceptable.
For INVOS adult and SenSmart adult we attached a brand-new sensor for one deoxygenation
at ctHb = 47.5 µM in phantom 3. Both showed exactly the same behavior as the old sensors
(Fig. 1(d) and 3(a)), suggesting negligible variation between individual sensors.
INVOS adult and OxyPrem v1.3 oximeters were investigated in [38] and in the present study
(Fig. 3(a) and 3(b)) enabling to determine the repeatability. Within the fitting range, differences
were < 3 %. Table 4 shows that linear transformation from present results (in rows) to those
of [38] (in columns) is y = 0.96∗ x+3.2 for INVOS adult and y = 0.96∗ x+2.6 for OxyPrem v1.3
and thus close to the perfect relationship of y = 1 ∗ x + 0. Table 3 further shows that uncertainty
range due to changes in ctHb is slightly increased compared to [38] for OxyPrem v1.3 at the
hypoxic threshold and for INVOS adult at the hyperoxic threshold. This increase is most likely
caused by the sensor re-mounting between the deoxygenations at ctHb = 47.5 µM which resulted
in a slight shift of values (Fig. 3(b)). Compared to [38], estimation of SafeBoosC action thresholds
only deviates by 1 % at the hypoxic threshold for INVOS adult and by 1 % at hyperoxic threshold
for OxyPrem v1.3 . We conclude that the phantom showed good reproducibility.
4.4. Implications of other haemoglobin species
The tested oximeters do not account for dyshaemoglobins, e.g. carboxy- and methaemoglobin,
or fetal Hb , so their presence could be a source of error depending on their concentration and
extinction coefficients [31]. We used adult donor blood for the phantom and hence fetal Hb
was not present. Fetal Hb has nearly the same absorption spectra as adult Hb [52]. So, even in
neonatal populations when fetal Hb may be dominant, this would at most introduce a negligible
error [53]. Methaemoglobin has extinction coefficients in the near-infrared range that are close to
those of oxygenated haemoglobin (O2Hb), while the carboxyhaemoglobin extinction coefficient
is negligible [52]. Normally, methaemoglobin is < 2 % of all Hb. Methaemoglobin was not
determined in the donor blood, but only increases slightly during storage [54]. No known agents
for the formation of methaemoglobin were used during the experiment and hence, we do not
consider methaemoglobin a likely source of error.
5. Conclusion
Extending our previous findings to further oximeter brands, we confirmed that different brands of
oximeters provide different tissue oxygen haemoglobin saturation (StO2) readings in a phantom
designed to mimic the head of preterm infants. Preliminary clinical data are in agreement with the
phantom results. We provided linear equations which translate data from one oximeter to another
at a total haemoglobin concentration (ctHb) typical for preterm infants. Accordingly, intervention
thresholds have to be set specifically for each brand and sensor type. Additionally, these thresholds
are subject to uncertainties arising from device-specific dependence of the StO2 readings on the
ctHb. Previous results were reproduced with < 3 % deviation. Reproducibility of hypoxic and
hyperoxic thresholds was ≈ 1%, and variation due to sensor removal and replacement was < 2%.
This demonstrates good reproducibility of the method.
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